Kadri Hachemi, Alamri Mubarak A, Navratilova Iva H, Alderwick Luke J, Simpkins Nigel S, Mehellou Youcef
School of Pharmacy, University of Birmingham, Edgbaston Park Road, Birmingham, B15 2TT, UK.
Division of Biological Chemistry and Drug Discovery, University of Dundee, Dow Street, Dundee, DD1 5EH, UK.
Chembiochem. 2017 Mar 2;18(5):460-465. doi: 10.1002/cbic.201600620. Epub 2017 Jan 30.
The binding of the scaffolding protein MO25 to SPAK and OSR1 protein kinases, which regulate ion homeostasis, causes increases of up to 100-fold in their catalytic activity. Various animal models have shown that the inhibition of SPAK and OSR1 lowers blood pressure, and so here we present a new indirect approach to inhibiting SPAK and OSR1 kinases by targeting their protein partner MO25. To explore this approach, we developed a fluorescent polarisation assay and used it in screening of a small in-house library of ≈4000 compounds. This led to the identification of one compound-HK01-as the first small-molecule inhibitor of the MO25-dependent activation of SPAK and OSR1 in vitro. Our data confirm the feasibility of targeting this protein-protein interaction by small-molecule compounds and highlights their potential to modulate ion co-transporters and thus cellular electrolyte balance.
支架蛋白MO25与调节离子稳态的SPAK和OSR1蛋白激酶结合,会使其催化活性提高多达100倍。各种动物模型表明,抑制SPAK和OSR1可降低血压,因此我们在此提出一种通过靶向其蛋白伴侣MO25来间接抑制SPAK和OSR1激酶的新方法。为探索该方法,我们开发了一种荧光偏振测定法,并将其用于筛选约4000种化合物的小型内部文库。这导致鉴定出一种化合物HK01,它是体外MO25依赖性激活SPAK和OSR1的首个小分子抑制剂。我们的数据证实了通过小分子化合物靶向这种蛋白质-蛋白质相互作用的可行性,并突出了它们调节离子共转运蛋白从而调节细胞电解质平衡的潜力。